These data prompted us to investigate potential combination candidate drugs that could enhance the therapeutic efficacy of KH‐4‐43 and help us focus on the impacts of CRL4 inhibition that may regulate its anti‐tumour effects in ovarian cancer. This evidence concerns the gene IL17RB and ovarian cancer.